secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akero Therapeutics, Inc. (—)
CIK:        0001744659
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001193125-24-060883
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akero Therapeutics to raise ~$299M in public offering of 11M shares at $29.00/share
--------------------------------------------------------------------------------

- Offering of 11,000,000 shares at $29.00 per share; underwriters have 30-day option for additional 1,650,000 shares.
- Net proceeds expected ~$299.4M (or ~$344.4M if option exercised in full).
- Proceeds to fund clinical development of efruxifermin (EFX) for NASH, including Phase 2b HARMONY and Phase 3 SYNCHRONY studies.
- Cash runway extended into 2027; company currently has no agreements for acquisitions or investments with proceeds.
- Offering expected to close March 8, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/0001193125-24-060883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/d808358d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-060883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer